The PTH (1-84)/non-PTH (1-84) ratio is a risk factor for cardiovascular events in hemodialysis patients

被引:8
|
作者
Zitt, E. [2 ,3 ]
Kirsch, A. H.
Haueis, M.
Strasak, A. [4 ]
Neyer, U. [2 ,3 ]
Mayer, G.
Rosenkranz, A. R. [1 ]
机构
[1] Med Univ Innsbruck, Univ Klin Innere Med 4, Dept Internal Med 4, A-6020 Innsbruck, Austria
[2] Acad Teaching Hosp Feldkirch, Dept Nephrol & Dialysis, Feldkirch, Austria
[3] VIVIT, Feldkirch, Austria
[4] Med Univ Innsbruck, Dept Med Stat, A-6020 Innsbruck, Austria
关键词
PTH; secondary hyperparathyroidism; PTH (1-84)/non-PTH (1-84) ratio; cardiovascular morbidity; cardiovascular mortality; hemodialysis; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; PARATHYROID-HORMONE ASSAYS; INCIDENT DIALYSIS PATIENTS; ALL-CAUSE MORTALITY; VASCULAR CALCIFICATION; BONE HISTOMORPHOMETRY; MINERAL METABOLISM; SERUM-CALCIUM; ASSOCIATION;
D O I
10.5414/CNP75309
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: We hypothesized that the PTH (1-84)/non-PTH (1-84) ratio (PTH ratio) might help to assess cardiovascular risk in hemodialysis patients. Methods: In this prospective cohort study 70 prevalent hemodialysis patients were followed up to 4 years. The PTH ratio was determined at base-line. Primary outcomes were cardiovascular events (CV E) and all-cause mortality. Cumulative event-free survival was compared between patients with a ratio < 1 and those with a ratio > 1. The risk-association of the PTH ratio with CVE was examined using an adjusted Multiple Cox Proportional Hazards model. Results: A PTH ratio > 1 was found in 34 patients (49%). During follow-up 26 patients suffered a CVE. Patients with a CVE showed a higher ratio than patients with event-free survival (p = 0.033). In patients with a ratio > 1 a significantly higher number of CVE occurred (53 vs. 22%; p = 0.013), and these patients showed a significantly shorter event-free survival (p = 0.032). In an adjusted Cox-proportional hazards model a higher PTH ratio was found to be independently associated with an elevated risk for CVE (HR = 3.2; 95% Cl 1.06 - 13.63; p = 0.04). Conclusions: A higher PTH (1-84)/non-PTH (1-84) ratio is associated with an increased risk for CVE in hemodialysis patients and might therefore be useful for cardiovascular risk estimation in this population.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 50 条
  • [1] PTH(1-84)/PTH(7-84): a balance of power
    Friedman, PA
    Goodman, WG
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2006, 290 (05) : F975 - F984
  • [2] Observation of parathyroid cancer patients reveals non-typical 1-84 PTH (NT 1-84 PTH) in one patient
    Cantor, T
    D'Amour, P
    Rubin, MR
    Silverberg, SJ
    Bilezikian, JP
    CLINICAL CHEMISTRY, 2005, 51 : A236 - A237
  • [3] PTH 1-84, PTH fragments and bone turnover
    Malluche, HH
    Monier-Faugere, MC
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (05) : 1127 - 1127
  • [4] Bone histology validation of the scantibodies 1-84 PTH (CAP) assay and the 1-84 PTH/Large C terminal PTH fragments ratio.
    Tokumoto, A
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 688A - 688A
  • [5] PTH(1-84) IN HYPERCALCEMIA OF MALIGNANCY
    FRASER, WD
    LANCET, 1992, 339 (8794): : 689 - 689
  • [6] The reversed ratio of 1-84 PTH (whole PTH)/intact PTH in a patient on hemodialysis associated with primary hyperparathyroidism
    Mizumura, Y.
    Mukaiyama, Y.
    Osada, H.
    Hida, O.
    Nishimiya, M.
    Nakamura, Y.
    CLINICAL NEPHROLOGY, 2008, 69 (04) : 310 - 312
  • [7] Measuring the effect of Cinacalcet on 1-84 PTH and 7-84 PTH
    Cantor, T
    Amerling, R
    Modugno, M
    Goretsky, S
    CLINICAL CHEMISTRY, 2005, 51 : A237 - A237
  • [8] CLINICAL EVALUATION OF NOVEL PTH(1-84) BIOINTACT ASSAYS IN HEMODIALYSIS PATIENTS
    Hecking, Manfred
    Kainz, Alexander
    Bielesz, Bernhard
    Plischke, Max
    Beilhack, Georg
    Hoerl, Walter H.
    Sunder-Plassmann, Gere
    Bieglmayer, Christian
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 492 - 492
  • [9] Significance of Bio-intact PTH(1-84) assay in hemodialysis patients
    Inaba, M
    Okuno, S
    Imanishi, Y
    Ueda, M
    Yamakawa, T
    Ishimura, E
    Nishizawa, Y
    OSTEOPOROSIS INTERNATIONAL, 2005, 16 (05) : 517 - 525
  • [10] A comparison of strontium ranelate and PTH(1-84)
    Henriksen, Kim
    Christiansen, Claus
    Karsdal, Morten A.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2011, 6 (02) : 153 - 155